If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for research-grade material |
| Solubility | Soluble in DMSO and ethanol; low aqueous solubility | Organic stock solutions are common |
| Typical storage temperature | -20 °C or lower | Protect from light and moisture |
| Common analytical method | LC-MS/MS | Used for detection and confirmation |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
yr, but in the past 40 years, the experimental scene has been dominated by the KamiokaNDE experiment and its successor Super-Kamiokande. The construction of KamiokaNDE experiment under the direction of Masatoshi Koshiba was completed in 1983. The detector was a cylindrical tank (16 m in height and 15.6 m in diameter) containing 3,000 tons of pure water, equipped with about 1,000 photomultiplier tubes (PMTs) arranged on the lateral surface. It was located in the Kamioka zinc mine (near the city of Hida, Gifu Prefecture, Japan). The photomultipliers detected Cherenkov light, emitted by charged particles traversing the water at speeds greater than the speed of light in the medium. KamiokaNDE was able to set stringent lower limits on the proton lifetime (
However, although the notion of obesity as a state of 'leptin resistance' has become ingrained in the minds of many researchers, data does not directly support this contention. For example, the work of Rudolph Leibel at Columbia University shows that, in both obese and lean individuals, leptin injections do not reduce body mass. The finding that both lean and obese subjects have a similar lack of response underscores the notion that the brain is not designed to respond to increased leptin by decreasing food intake; rather, lack of leptin acts as a signal to increase food intake. Indeed, Leibel's work has shown that the decreases in serum leptin that occur post-weight-loss constitute a state of leptin deficiency, which drives increased appetite with weight loss. As such, leptin injections in weight-reduced patients can prevent increases in appetite and thereby allow patients to maintain weight loss. These studies, therefore, demonstrate that leptin treatment may be a useful strategy to treat obesity in humans, if not by driving weight loss directly then by allowing weight loss (as a result of diet and exercise) to be more readily maintained. Moreover, as geneticists learn more from the few cases of leptin gene mutations, the possibility remains that, although leptin was ineffective at treating obesity across the population, some individual obese patients might still benefit from its use as an anti-obesity medication. Research into the adipose-derived hormones adiponectin and resistin is ongoing. Like leptin, these hormones also affect energy balance and metabolism.
They were moved to the Château de Facqueval in Modave, Belgium, where Hahn used the time to work on his memoirs and then, on 3 July, were flown to England. They arrived at Farm Hall, Godmanchester, near Cambridge, on 3 July. While they were there, all their conversations, indoors and out, were covertly recorded with hidden microphones. They were given British newspapers, which Hahn was able to read. He was greatly disturbed by their reports of the Potsdam Conference, where German territory was ceded to Poland and the USSR. In August 1945, the German scientists were informed of the atomic bombing of Hiroshima. Up to this point the scientists, except Harteck, were completely certain that their project was further advanced than any in other countries, and the Alsos Mission's chief scientist, Samuel Goudsmit, did nothing to correct this impression. Now the reason for their incarceration in Farm Hall suddenly became apparent. As they recovered from the shock of the announcement, they began to rationalise what had happened. Hahn noted that he was glad that they had not succeeded, and von Weizsäcker suggested that they should claim that they had not wanted to. They drafted a memorandum on the project, noting that fission was discovered by Hahn and Strassmann. The revelation that Nagasaki had been destroyed by a plutonium bomb came as another shock, as it meant that the Allies had not only been able to conduct uranium enrichment, but had mastered nuclear reactor technology as well. The memorandum became the first draft of a postwar apologia.
==== Nervous system ==== There are nerve cells, also known as neurons, present in the human body. They are branched out. These cells make up nervous tissue. A neuron consists of a cell body with a nucleus and cytoplasm, and cytoplasmic protrusions of an axon, and dendrites.
==== Mild phenotype ==== There is an ultra-rare mild phenotype caused by recessive heterozygous alleles in the PYGM gene, where one allele is a common exon mutation and the other allele is an ultra-rare intronic mutation. It can also be caused by recessive homozygous intronic mutations. These intronic mutations result in a milder phenotype compared to the classic phenotype of McArdle disease. There is residual myophosphorylase activity, between 1-2% residual activity compared to unaffected individuals. This results in greater exercise capacity compared to classic phenotype McArdle individuals, particularly for sustained aerobic activity, but the capacity was still below that of unaffected individuals. In this mild phenotype, since their early teens, they did experience cramping and premature muscle fatigue during sudden vigorous exercise and prolonged isometric exercise; however, due to their less diminished capacity for aerobic activity, they were able to keep up with their peers in sports and everyday activities. As of 2009, there have been 3 reported cases of non-related individuals, a reported Druze family of consanguineous (related) individuals and 9 reported cases in two Finnish families.
Sources: en.wikipedia.org
radioligands) have been developed for PET that are ligands for specific neuroreceptor subtypes such as [11C]raclopride, [18F]fallypride and [18F]desmethoxyfallypride for dopamine D2/D3 receptors; [11C]McN5652 and [11C]DASB for serotonin transporters; [18F]mefway for serotonin 5HT1A receptors; and [18F]nifene for nicotinic acetylcholine receptors or enzyme substrates (e.g. 6-FDOPA for the AADC enzyme). These agents permit the visualization of neuroreceptor pools in the context of a plurality of neuropsychiatric and neurologic illnesses. PET may also be used for the diagnosis of hippocampal sclerosis, which causes epilepsy. FDG, and the less common tracers flumazenil and MPPF have been explored for this purpose. If the sclerosis is unilateral (right hippocampus or left hippocampus), FDG uptake can be compared with the healthy side. Even if the diagnosis is difficult with MRI, it may be diagnosed with PET. The development of a number of novel probes for non-invasive, in-vivo PET imaging of neuroaggregate in human brain has brought amyloid imaging close to clinical use. The earliest amyloid imaging probes included [18F]FDDNP, developed at the University of California, Los Angeles, and Pittsburgh compound B (PiB), developed at the University of Pittsburgh. These probes permit the visualization of amyloid plaques in the brains of Alzheimer's patients and could assist clinicians in making a positive clinical diagnosis of Alzheimer's disease pre-mortem and aid in the development of novel anti-amyloid therapies.
=== Palmar and plantar aponeuroses and extensor hood === The palmar aponeuroses occur on the palms of the hands. The extensor hoods are aponeuroses at the back of the fingers. The plantar aponeuroses occur on the plantar aspect of the foot. They extend from the calcaneal tuberosity then diverge to connect to the bones, ligaments and the dermis of the skin around the distal part of the metatarsal bones.
== Manufacturing == Although pseudoephedrine occurs naturally as an alkaloid in certain plant species (for example, as a constituent of extracts from the Ephedra species, also known as ma huang, in which it occurs together with other isomers of ephedrine), the majority of pseudoephedrine produced for commercial use is derived from yeast fermentation of dextrose in the presence of benzaldehyde. In this process, specialized strains of yeast (typically a variety of Candida utilis or Saccharomyces cerevisiae) are added to large vats containing water, dextrose and the enzyme pyruvate decarboxylase (such as found in beets and other plants). After the yeast has begun fermenting the dextrose, the benzaldehyde is added to the vats, and in this environment, the yeast converts the ingredients to the precursor l-phenylacetylcarbinol (L-PAC). L-PAC is then chemically converted to pseudoephedrine via reductive amination. The bulk of pseudoephedrine is produced by commercial pharmaceutical manufacturers in India and China, where economic and industrial conditions favor its mass production for export.
In 2001, they published a retraction after researchers at other laboratories were unable to duplicate the results and the Berkeley lab could not duplicate them either. In June 2002, the director of the lab announced that the original claim of the discovery of these two elements had been based on data fabricated by principal author Victor Ninov. Newer experimental results and theoretical predictions have confirmed the exponential decrease in cross sections with lead and bismuth targets as the atomic number of the resulting nuclide increases.
Sources: en.wikipedia.org
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.
Liquid chromatography with tandem mass spectrometry is widely used to detect and confirm SR9009 in laboratory samples. The technique offers high sensitivity and can distinguish the target compound from related substances. Nuclear magnetic resonance and ultraviolet detection may support identity and purity checks.
Online products labeled as SR9009 may vary in identity, purity, and actual content. Independent testing helps confirm that a sample matches its label and does not contain unexpected contaminants. This is important for reproducible research and for interpreting experimental results.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.